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Aims & Objectives 
The aim of this treatment planning study is to compare the
techniques of 3D conformal radiotherapy (3DCRT) and IMRT to
determine the feasible advantages for prostate cancer patients
using a new direct step & shoot (DSS) IMRT module.
For the optimisation of the IMRT, Nucletron offers as a part of the
optimising process their IM-optimisation software or their new
module DSS. The earlier IM-optimisation software searches first
for the ideal fluence for each beam, and this is then followed by
the segmentation. The new DSS module integrates the
segmentation into the optimisation process. After that both
continue with the final dose calculation.
Materials & Methods
Between March 2006 and November 2006, four patients with a mean
age of 71 years were enrolled for primary EBRT for localised prostate
cancer. Three of these patients received antiandrogen therapy either
before or during radiotherapy. All four patients had 3D CT treatment
planning with a slice thickness of 5 mm and with immobilisation in a
vacuum mattress (BlueBAG BodyFIX, Medical Intelligence).
As an initial step, it was planned (using Oncentra MasterPlan) to
deliver 60 Gy to the planning target volume (PTV), calculated using
data for a Siemens Primus linear accelerator (15 MV photons, with
multileaf collimator leaf width of 1cm at the isocentre). The
preselected gantry angles were 25o, 90o, 120o, 240o, 270o and 335o.
The rectal volume and urinary bladder were delineated as organs at
risk (OARs). Additional structures were also contoured in order to
help (we term them ‘Help Contours’) avoid hot spots in normal tissues
surrounding the PTV to a distance of 1cm. The dose-volume
objectives were defined by two schemes (Table 1). After optimisation
the plans were re-normalised to the average of PTV, giving 30
fractions with a fractional dose of 2 Gy. The 3DCRT plan used
identical gantry angles with the beams weighted by experience.
Results
Both IMRT optimisation schemes reduced the doses received by the
OARs when compared to the 3DCRT plan. Using the Nucletron IM-
optimisation software the first weighting scheme of the objectives
resulted in satisfactory dose-volume histograms (DVHs) for the
OARs, and an obviously 'softened' DVH for the PTV (when
compared to the 3DCRT plan). The DSS optimisation produced a
steeper DVH for the PTV, but worse results for the OARs when
compared to the IM-optimisation.
Scheme 2 improved the DVHs for the OARs using the DSS process,
to about the same level as the IM-optimisation with scheme 1, the
PTV DVH staying nearly unchanged. The IM-optimisation produced
the worst DVH for the PTV of the five different plans we considered.
In Figure 1 the DVHs are shown of a characteristic 3DCRT plan, the
IM plan (Scheme 1) and the DSS plan (Scheme 2). Table 2 presents
the mean values, averaged over the four patients, for the PTV and
for the two OARs.
Conclusions
In every case the DSS optimisation resulted in a steeper DVH for the PTV
than found using the IM process. The DVHs for the OARs are worse with
scheme 1 but improve to about the same level with scheme 2. The patients
benefit from IMRT by reduced doses to the OARs, keeping a very steep
DVH for the PTV with the DSS optimisation.
Figure 1: DVHs for one characteristic case in three different plans
Table2: Mean dose values in different regions, averaged 
over five plans
mean in PTV [Gy] mean in bladder [Gy] mean  in rectum [Gy]
3D conmformal 60,3 33,8 41,1
IM scheme 1 60,2 29,6 30,7
DSS scheme 1 60,1 30,3 33,4
IM scheme 2 60,3 28,2 28,5
DSS scheme 2 60,2 28,0 29,8
Scheme
PTV Minimum 
Dose [Gy]    Weight
PTV Maximum 
Dose [Gy]   Weight
OAR 20% Vol. 
Dose [Gy]   Weight
Help contours Max. 
Dose [Gy]   Weight
1   59               3000   64              3000   40               100   55               300
2   59               3000   64              3000   40              3000   55               300
Table1: Dose-volume objective schemes
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